Latest Posts › Patent Litigation

Share:

Federal Circuit Provides Guidance on What Claims Can Properly Serve As Obviousness-Type Double Patenting References

In a precedential decision issued on August 13, 2024, the U.S. Court of Appeals for the Federal Circuit held that a first-filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued,...more

The PTAB Review - August 2024

This issue of The PTAB Review begins by providing an analysis of how institution decisions consider declaration testimony submitted by a patent owner. Next, it summarizes proposed rulemaking from the United States Patent and...more

USPTO Proposes New Requirement for Terminal Disclaimers That Amounts to a Significant Change from Current Practice

On May 10, 2024, the United States Patent and Trademark Office (USPTO) issued a notice of proposed rulemaking to add a new requirement for terminal disclaimers filed to obviate nonstatutory double patenting rejections to the...more

The PTAB Review - April 2024

This issue of The PTAB Review begins by summarizing a recent Patent Trial and Appeal Board (PTAB) decision strictly applying the public availability standard for prior art references as a basis for denying institution. Next,...more

2023 PTAB Year in Review

Wilson Sonsini Goodrich & Rosati is pleased to present our 2023 PTAB Year in Review. We begin with a review of 2023 petition filings and outcomes at the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and...more

The PTAB Review - September 2023

In this edition, we begin with a discussion of recent trends in sanctions practice at the Patent Trial and Appeal Board (PTAB). Next, we summarize several recent Federal Circuit decisions addressing various aspects of PTAB...more

The PTAB Review - May 2023

This issue begins with a summary of several Patent Trial and Appeal Board (PTAB) policy questions the U.S. Patent and Trademark Office (USPTO) has raised in an advance notice of proposed rulemaking. Next, we examine two...more

Federal Circuit Affirms Jazz Pharmaceutical's Risk Evaluation and Mitigation Strategy Patent Is Not Listable in Orange Book

On February 24, 2023, the Federal Circuit held that Jazz Pharmaceuticals, Inc. (Jazz) must delist U.S. Patent No. 8,731,963 (the ’963 Patent) from the U.S. Food and Drug Administration’s (FDA’s) “Orange Book” because the...more

The PTAB Review - October 2022

This issue of The PTAB Review begins with a brief update about the U.S. Patent & Trademark Office (USPTO) Guidelines for when institution of an America Invents Act (AIA) trial (e.g., inter partes review or post-grant review)...more

The PTAB Review - June 2022

This issue of The PTAB Review begins with two brief updates about the power of the Patent Office Director to review Patent Trial and Appeal Board (PTAB) decisions. Next, we examine a special circumstance under which a patent...more

The PTAB Review - November 2021

This issue of The PTAB Review begins with a brief summary of changes to America Invents Act (AIA) trials recently proposed in Congress. It then explores a recent Federal Circuit decision rejecting arguments that the Patent...more

Patent Stakeholders Invited to Provide Public Comment on Patent Eligibility Impacts on American Innovation

On July 9, 2021, the United States Patent and Trademark Office (USPTO) published a notice in the Federal Register on behalf of Senators Tillis, Hirono, Cotton, and Coons seeking public input for a patent eligibility...more

The PTAB Review - July 2021

This issue of The PTAB Review begins with a brief summary of the U.S. Supreme Court’s most recent pronouncement about America Invents Act (AIA) reviews. It then provides an update on the Patent Trial and Appeal Board’s...more

The PTAB Review - April 2021

In this edition, we examine the effect of Fintiv on PTAB proceedings dealing with patents asserted in so-called “rocket docket” courts. Next, we provide a brief summary of several recent Federal Circuit cases. We conclude by...more

2020 PTAB Year in Review

The firm's post-grant practice is pleased to present its 2020 PTAB Year in Review. The publication begins with a review of 2020 petition filings at the Patent Trial and Appeal Board (PTAB) and takes a closer look at the...more

The PTAB Review - October 2020

In this edition, we discuss an update on the Arthrex Appointments Clause decision. We examine the continuing demise of same-party joinder and deference to Patent Trial and Appeal Board (PTAB) precedential decisions, and the...more

Patent Trial and Appeal Board Issues Decision on CRISPR Patent Priority Dispute

On September 10, 2020, the Patent Trial and Appeal Board (PTAB) decided key motions in Interference No. 106,115, University of California v. Broad Institute. The interference involves 10 patent applications of the University...more

Patent Trial and Appeal Board Hears Argument in CRISPR Patent Priority Dispute

On May 18, 2020, the Patent Trial and Appeal Board (PTAB) heard argument in Interference No. 106,115, University of California1 v. Broad Institute2. The interference involves 10 patent applications of University of California...more

Supreme Court: PTAB Decisions "Closely Related" to Institution—Such as the One-Year Time Bar—Are Not Appealable to the Federal...

The America Invents Act (AIA) authorizes the Patent Trial and Appeal Board (PTAB) to cancel patent claims that never should have been issued but prohibits the PTAB from acting on petitions for review brought more than one...more

Patent Post-Grant Proceedings Continue Despite Covid-19 Disruptions

The Patent Trial and Appeal Board (PTAB) and the United States Court of Appeals for the Federal Circuit (CAFC) have made adjustments in their practices to accommodate the new realities of COVID-19 and social distancing, but...more

Federal Circuit Upholds Patents Drawn to Methods of Separating Fetal Cell-Free DNA from Maternal Cell-Free DNA

The Federal Circuit, in Illumina, Inc., v. Ariosia, reversed the summary judgment decision of a lower trial court and upheld—as patent subject matter eligible—claims in two patents (U.S. 9,580,751; U.S. 9,738,931). The...more

Diagnostic Patent Take-Home Lessons from the Recent Federal Circuit Athena Case

Recently, the U.S Court of Appeals for the Federal Circuit issued a split panel decision in Athena.Athena, which examined the patent subject matter eligibility of four claims in one issued patent, upheld a district court's...more

The PTAB Review - June 2018

Orange Book-Listed Patents Prove to Be Popular Targets for AIA Challenges - On March 13, 2018, Chief Administrative Patent Judge Ruschke of the Patent Trial and Appeal Board (PTAB) released findings of the Patent Office’s...more

Federal Circuit Hears Argument in CRISPR Patent Priority Dispute

Today, the U.S. Court of Appeals for the Federal Circuit heard argument in University of California v. Broad Institute on whether the Patent Trial and Appeal Board (PTAB) correctly held that both the University of California...more

Supreme Court Issues Two Decisions Impacting Practice Before the Patent Trial and Appeal Board

Today, the U.S. Supreme Court issued two decisions that will keep the Patent Trial and Appeal Board (PTAB) busier than ever. In Oil States Energy Services, LLC v. Greene's Energy Group, LLC,1 the Court affirmed that inter...more

31 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide